Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Olmesartan French Delisting Delayed, But Still Big Hit For Daiichi Sankyo

Executive Summary

The antihypertensive olmesartan is to lose its reimbursement status in France next year, on the grounds that its efficacy had been shown to be less convincing that that of other angiotensin receptor blockers.

You may also be interested in...



UK To Go Ahead With Pre-Licensing Use Of COVID-19 Vaccines

A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded. 

NICE OKs Sarclisa & Mayzent For Funding In England, But Rejects Vindaqel

The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.

England’s HTA Body To Overhaul Product Selection Process

Proposals from NICE that are out for consultation are intended to boost the HTA body’s efficiency, improve transparency and governance, and raise the quality of its guidance.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel